- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech

- SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties

- Genentech will be responsible for the subsequent clinical...